Use broad spectrum sunscreen (SPF15 or more) 15mins in advance

Jul 15 - Waiting before sun exposure provides the most sunscreen protection

Learn More

Clinical Investigator Training Course Nov 12 - 14, 2019

Register to learn about clinical trials, FDA’s requirements

Jul 15 - Course covers investigator responsibilities, trial design, data review

Drug approved for urinary tract and intra-abdominal infections

Jul 17 - Expands treatment options for patients with complicated infections

Tests show skin absorbs certain sunscreen active ingredients

Jul 8 - FDA advises consumers to continue using sunscreen

Drug Information, Safety, and Availability

Medication Guides, Drug Safety Communications, Shortages, Recalls

Drug Approvals and Databases

Drugs@FDA, Orange Book, National Drug Code, Recent drug approvals

Drug Development and Review Process

Drug applications, submissions, manufacturing, and small business help

Guidance, Compliance & Regulatory Information

Guidances, warning letters, drug compounding, registration and listing

Regulatory Science Research and Education

CDER research programs, initiatives, resources, and CDERLearn education

Emergency Preparedness

Prepare and respond to natural disasters, nuclear and chemical attacks

Updates, News, and Events

Recent approvals, meetings, workshops, blogs, podcasts, stay connected

About the Center for Drug Evaluation and Research (CDER)

Our role, mission, organization, history, leadership, job openings

Consumers and Patients

Find drug information. Report drug side effects. Learn how to buy, use, and dispose of unused drugs. Attend a public meeting.

Health Care Professionals

Get drug safety, recall, and shortage information. Report drug adverse events. Find jobs at FDA. Watch training/education videos and courses.

Industry

Search drug databases. Find guidance, submission, user fee, and meeting information. Get small business assistance. Find jobs at FDA.

Opioids

Reducing the impact of opioid misuse and abuse

Generics

Ensuring access to safe, affordable, and effective generic drugs

Warning Letters

Warning and Notice of Violation Letters to Pharmaceutical Companies

Guidances

FDA's current thinking on drug development and review activities

Drug Development Tools Qualification Program

Using scientific and technical innovations for better drug development

21st Century Cures at CDER

Bringing innovative and advanced medicines to patients faster

Expanded Access (Compassionate Use)

Providing access to investigational drugs outside of clinical trials

Director's Corner

CDER Center Director Dr. Janet Woodcock speaking on drug-related topics

Risks associated with the investigational use of Venclexta in Multiple Myeloma

Mar 21 - FDA issues Alert based on data from a clinical trial.

Harm reported from sudden discontinuation of opioid pain medicines

Apr 09 - FDA requires label changes to guide prescribers on gradual, individualized tapering

Updates on Angiotensin II Receptor Blocker (ARB) Recalls

Apr 29 - Latest news on ARBs - medicines used to treat high blood pressure and heart failure

Center

Jul 16

Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Over-The-Counter Ophthalmic Products Sold By Accutome, Focus Laboratories, Grandall Distributing Co. Inc. And Prestige

Jul 16

Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Over-The-Counter Ophthalmic Products Sold By Natural Ophthalmics And TRP Company, Inc.

Jul 15

Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products Sold by OCuSOFT

Center

Jul 17

FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections

Jul 03

FDA approves new treatment for refractory multiple myeloma

More Press Announcements

Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993

druginfo@fda.hhs.gov

Toll Free

(855) 543-3784

(301) 796-3400

Hours Available

CDER Division of Drug Information